** Shares of drug developer OS Therapies rise 56.5% to $6.46 premarket
** Co says its experimental immunotherapy met the main goal of a mid-stage trial to treat a type of bone cancer
** Co says the therapy, OST-HER2, met the main goal of delaying the recurrence of the cancer by 12 months, compared to the historical comparable group
** Co says all patients who achieved the 12-month event-free survival goal are alive
** OST-HER2 was safe and well-tolerated in the study, OSTX says
** The therapy is being tested to prevent lung metastatic osteosarcoma, a type of recurrent bone cancer that has spread to the lungs
** Co says with these results, it is preparing to engage with U.S. FDA on "an accelerated pathway for approval"
** "We do not expect to have to treat additional patients as part of this process with FDA," OSTX adds
** Stock up 65.7% since its market debut in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.